Abstract
Introduction: Women with breast cancer have better cancer-related outcomes with the use of aromatase inhibitors (AIs), but the physiological suppression of estradiol can negatively affect sexual functioning due to unpleasant urogenital and vaginal symptoms. Local health care practitioners have observed that the benefits of vaginal testosterone in allaying these unpleasant symptoms in women with breast cancer are similar to the benefits of vaginal estrogen in women without breast cancer.|Aim: To evaluate the effects of using a daily vaginal testosterone cream on the reported sexual health quality of life in women with breast cancer taking AI therapy.|Methods: Thirteen postmenopausal women with breast cancer on AI therapy and experiencing symptoms of sexual dysfunction were recruited from an oncology practice. The women were prescribed a 300 microgram (μg) testosterone vaginal cream daily for 4 weeks. During the first study visit, a vaginal swab was obtained to rule out the presence of Candida species or Gardnerella vaginalis in participants. Women with positive vaginal swabs were treated prior to starting the vaginal testosterone therapy.|Main outcome measure: The Female Sexual Function Index (FSFI) survey, measuring female sexual health quality of life, was administered during the first study visit and at the final study visit, after completing testosterone therapy.|Results. Twelve patients completed four weeks of daily vaginal testosterone therapy. When compared to baseline FSFI scores, there was a statistically significant improvement for individual domain scores of desire (P=0.000), arousal (P=0.002), lubrication (P=0.018), orgasm (P=.005), satisfaction (P=0.001), and pain (P=0.000). Total domain scores reflecting sexual health quality of life also improved when compared to baseline (P=0.000).|Conclusions. The use of a compounded testosterone vaginal cream applied daily for four weeks improves reported sexual health quality of life in women with breast cancer taking AIs.